PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, gained accelerated approval by the National Medical Products Administration (NMPA) in China.
PRESS RELEASES
October 16, 2024
Sound Biologics Announces Breakthrough Approval of PSB205 by the NMPA
June 3, 2022
Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity
April 13, 2021
Sound Biologics Announces Proof-of-Concept Success at AARC Annual Meeting
Phase 1 Study results for PSB205, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, provides proof-of-concept and early clinical validation of the MabPair platform
April 10, 2019
Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors
—
